Compare Honest Company Inc (HNST) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honest Company Inc vs Merck & Co., Inc. — how do they compare? Honest Company Inc trades at $5.04 (market cap $533.20M), while Merck & Co., Inc. trades at $145.55 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 658.8× Honest Company Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Honest Company Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Honest Company Inc for 39 Days and Merck & Co., Inc. for 98 Days on average.
| HNST | MRK | |
|---|---|---|
Market Cap | $533.20M | $351.28B |
Volume | 1,990,155 | 7,969,665 |
Sector | Consumer Staples | Health |
52-Week High | $5.95 | $156.43 |
52-Week Low | $2.10 | $82.49 |
Typical Hold Time | 39 Days | 98 Days |
Enterprise Value | $436.81M | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HNST trades at $4.99, up 1.22% today, with a bearish technical signal despite recent positive earnings momentum. The company shows mixed fundamentals with revenue of $371.32M in 2025 but negative net income margins. Recent Q2 2026 earnings beat expectations with $0.04 EPS, and institutional interest is growing with BlackRock's $25.66M investment in August 2026.
The stock faces headwinds from persistent unprofitability and declining revenue projections for 2026, though strategic exits are improving margins. Analyst consensus is mixed with a $5.30 price target, suggesting limited upside. Key risks include execution on profitability and competitive pressures in personal care markets.
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Honest Company Inc
The Honest Co Inc is a consumer products company. It offers eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products and other products.
Read more on HNST →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
